

# CLINICAL PHARMACOLOGY & THERAPEUTICS

## CO-EDITORS

Walter Modell, M.D.  
Marcus M. Reidenberg, M.D.

## MANAGING EDITOR

June Reidenberg

## EDITORIAL BOARD

Alvito P. Alvares, Ph.D.  
Daniel L. Azarnoff, M.D.  
Thorir D. Bjornsson, M.D.  
Terrence F. Blaschke, M.D.  
Paul Calabresi, M.D.  
Donald B. Calne, M.D.  
Edward A. Carr, Jr., M.D.  
Allan H. Conney, Ph.D.  
T. S. Danowski, M.D.  
Peter Dineen, M.D.  
Edward F. Domino, M.D.  
Dennis E. Drayer, Ph.D.  
Alvan R. Feinstein, M.D.  
Robert B. Forney, Ph.D.  
Emil Frei III, M.D.  
Milo Gibaldi, Ph.D.  
Arthur Hull Hayes, Jr., M.D.  
Leonard Horowitz, M.D.  
Aryeh Hurwitz, M.D.  
Murray E. Jarvik, M.D.  
Anthony Kales, M.D.  
Werner Kalow, M.D.

## ASSOCIATE EDITORS

Arthur J. Atkinson, Jr., M.D.  
Paul D. Stolley, M.D., M.P.H.  
Raymond L. Woosley, M.D., Ph.D.

Stanley A. Kaplan, Ph.D.  
Arthur S. Keats, M.D.  
Henn Kutt, M.D.  
Louis Lasagna, M.D.  
Paul S. Lietman, M.D., Ph.D.  
Louis Lemberger, M.D., Ph.D.  
Gerhard Levy, Pharm.D.  
T. A. Loomis, M.D., Ph.D.  
David T. Lowenthal, M.D.  
Arno G. Motulsky, M.D.  
Harold C. Neu, M.D.  
Alan S. Nies, M.D.  
Lawrence G. Raisz, M.D.  
Lewis B. Sheiner, M.D.  
Robert Temple, M.D.  
Leroy D. Vandam, M.D.  
Elliot S. Vesell, M.D.  
John G. Wagner, Ph.D.  
E. Leong Way, Ph.D.  
Richard Weinshilboum, M.D.  
Louis Weinstein, M.D.  
Alastair J. J. Wood, M.B.Ch.B.

VOLUME 38, JULY-DECEMBER 1985  
THE C. V. MOSBY COMPANY, ST. LOUIS

Volume 38  
Copyright © 1985 by  
The C. V. Mosby Company

*All rights reserved*

*Printed in the United States of America*

## Index to volume 38

### Author index

#### A

Abernethy DR, 342, 697  
 Abraham PA, 31  
 Ajayi AA, 560  
 Ajzen H, 613  
 Akagi K, 290  
 Albin HC, 285  
 Alradi AO, 495  
 Alván G, 241, 394  
 Ambre JJ, 318  
 Anderson SA, 674  
 Anslow JA, 533  
 Anton RF, 52  
 Apicella M, 150  
 Araujo P, 533  
 Aronoff GR, 212  
 Arvela P, 652  
 Atkinson AJ Jr, 318  
 Atkinson RL, 419

#### B

Bachofen H, 96  
 Baker EL, 656  
 Baliga G, 266  
 Barnes JS, 258  
 Bayliff CD, 457  
 Beguin J, 549  
 Benet LZ, 121, 481  
 Berger A, 28  
 Berglund G, 188  
 Berke LK, 419  
 Berthelin C, 549  
 Besnard M, 549  
 Bibbs ML, 419  
 Bigelow GE, 219  
 Bigot M-C, 549  
 Bircher J, 618  
 Bodey GP, 134  
 Bongaerts MCM, 301  
 Bosso JA, 121

Bouchet JL, 285  
 Boutagy J, 371  
 Bowsher DJ, 318  
 Branch RA, 402, 414  
 Brater DC, 674  
 Brittain DC, 590  
 Brown-Cartwright D, 674  
 Bugiardini R, 101  
 Burckart GJ, 296  
 Burns T, 77, 642  
 Byington RP, 509

#### C

Cafarell R, 150  
 Calimlim JF, 177  
 Calissendorff B, 37  
 Camf J, 336  
 Campbell BC, 560  
 Carruthers SG, 495  
 Carson JL, 359  
 Challis P, 625  
 Chen A, 674  
 Chiang W-T, 37  
 Chow MJ, 318  
 Christiaanse JC, 301  
 Clarke J, 266  
 Cohen AF, 381  
 Collins JM, 45  
 Conrad KA, 331  
 Crawford MH, 538  
 Crivelli AM, 96  
 Cunci R, 439

#### D

Dahlqvist R, 37  
 Danan G, 439  
 Darke A, 533  
 Davies RO, 65  
 Davis R, 12  
 Dayer P, 488

Debruyne D, 549  
 Demotes-Mainard FM, 285  
 de Prost D, 171  
 de Simone G, 434  
 de Torres S, 336  
 DeVane CL, 586  
 DiPette DJ, 199  
 Dommissie CS, 586  
 Draibe SA, 613  
 Drake CR, 419  
 du Souich P, 686  
 Dvornik D, 625

#### E

Echizen H, 71  
 Eckfeldt JH, 157  
 Edgar B, 205  
 Edwards KDG, 313  
 Egan B, 519  
 Eichelbaum M, 71  
 Ellis GM Jr, 572  
 Emilsson H, 37  
 Erill S, 365  
 Erlinger S, 439  
 Eshelman FN, 157  
 Evans RR, 199

#### F

Fasano ML, 434  
 Faure G, 6  
 Feldman RD, 350  
 Ferrara LA, 434  
 Ferraro JC, 199  
 Ferrini D, 101  
 Fine RL, 45  
 Finley DK, 157  
 Fischer LJ, 350  
 Fischman MW, 318  
 Fleming JJ, 409  
 Flowers OV, 273  
 Foley KM, 631  
 Folgering HTM, 428  
 Fortner G, 273

Foulds G, 692  
 Freeman DJ, 56  
 Fujishima M, 462  
 Furberg CD, 509

#### G

Gagliardi R, 434  
 Galeazzi RL, 96, 140  
 Galvani M, 101  
 Gebhard RL, 157  
 George CF, 387  
 Gerber JG, 258  
 Goldberg MJ, 350  
 Goldstein S, 661  
 Gonzalez R, 625  
 Gore R, 195  
 Goto F, 402  
 Grabinski PY, 631  
 Graham DY, 65  
 Greenberg BD, 656  
 Greenblatt DJ, 595, 648, 697  
 Gridelli C, 101  
 Guerot C, 171  
 Guerra D, 336  
 Gugger M, 96

#### H

Hakala TR, 296  
 Haley NJ, 164  
 Halstenson CE, 31  
 Hamilton M, 381  
 Hardy BG, 457  
 Harmatz JS, 697  
 Harris K, 661  
 Hasegawa J, 306  
 Hawes EM, 128  
 Hayashi K, 462  
 Hedner T, 188  
 Hermens WAJJ, 469  
 Herskovic JE, 450  
 Hichens M, 661  
 Hicks D, 625  
 Hirakata H, 462

Hirose T, 590  
Ho DH, 134  
Hobbes J, 371  
Hoffman D, 164  
Hofkamp HG, 301  
Holmes GI, 65  
Holtzman JL, 157  
Honc F, 251  
Hooper JW, 533  
Hori R, 290  
Hunninghake DB, 313  
Hunter T, 228  
Hurwitz A, 642

**I**

Inturrisi CE, 631  
Irvin JD, 661  
Iselius L, 394  
Isles AF, 89

**J**

Jacob GB, 674  
Jacqz E, 402  
Jamali F, 325  
James A, 680  
Janicke D, 150  
Janky D, 642  
Jarvik ME, 450  
Jasinski DR, 544  
Jenkins JF, 45  
Johansson L, 205  
Johnson SL, 331  
Johnsson G, 205  
Judson BA, 572  
Juhl RP, 525  
Julius S, 519  
Jusko WJ, 150

**K**

Kaiko RF, 631  
Kaiser DL, 419  
Kamiya A, 290  
Karim A, 77, 642  
Karsenty F, 171  
Kassem N, 503  
Kater CE, 613  
Kauffman R, 183  
Keane WF, 31  
Keirns JJ, 278  
Kendall C, 28  
Kennedy GT, 538  
Kershaw RA, 251  
Kilpatrick SJ, 273  
Kinsella TJ, 45

Klecker RW, 45  
Klein L, 661  
Klotz U, 652  
Knirsch AK, 692  
Kochak GM, 251  
Korchinski ED, 128  
Koren G, 680  
Koshakji RP, 579  
Kradjan WA, 12  
Krantz KD, 28  
Kroboth PD, 525  
Kronbach T, 488  
Kuhlmann J, 667  
Küpfer A, 414, 618

**L**

Labetalol/Hydrochlorothiazide Multicenter Study Group, 24  
Lacouture PG, 183  
Lai AA, 586  
Laizure SC, 586  
Lammers J-WJ, 428  
Langendijk PNJ, 121  
Larochelle P, 686  
Lasagna L, 177  
Lauterburg BH, 566  
LeBlanc B, 134  
Lenzi S, 101  
LeRoy AA, 359  
Letz R, 656  
Levy G, 6  
Li CH, 631  
Liebson IA, 219  
Liedholm H, 475 (letter)  
Lin ET, 306  
Lindsten J, 394  
Littman GS, 16  
Locker B, 549  
Locniskar A, 697  
Löffberg I, 205  
Louik C, 183  
Lovejoy FH Jr, 183  
Lowenthal DT, 661  
Ludden TM, 475 (letter), 538  
Lundborg P, 205

**M**

MacDougall B, 228  
MacGregor TR, 278  
MacLeod SM, 89  
Magnusson A, 37  
Mahachai V, 325  
Malé P-J, 488

Maloy JW, 503  
Mann MA, 572  
Mari L, 101  
Maronde RF, 503  
Martin M, 199  
Martin WS, 533  
Martin-Dupont C, 285  
Matlis R, 648  
Mattei E Jr, 613  
Matzek KM, 278  
Matzke GR, 31  
Max MB, 631  
Mayersohn M, 331  
McAllister CB, 402  
McBurney A, 409  
McCabe EJ, 60  
McGourty JC, 409  
McKay G, 128  
McIntyre KM, 509  
McLean A, 475 (letter)  
Medakovic M, 503  
Meeran MK, 60  
Meier UT, 488  
Melandar A, 475 (letter)  
Merkus FWHM, 469  
Merrill D, 661  
Meyer UA, 488  
Micalizzi E, 195  
Midha KK, 128  
Miller RD, 692  
Mitchell AA, 183  
Mitchell JR, 566  
Mitenko PA, 228  
Montay G, 439  
Moore PA, 656  
Morisset R, 686  
Morse G, 150  
Morse ML, 359  
Morton A, 52  
Motomura K, 462  
Mottonen LR, 157  
Moulin M, 549  
Mullane JF, 625  
Musselman D, 195

**N**

Nakamura K, 402  
Nakano H, 290  
Nelson G, 266  
Netter P, 6  
Neu HC, 590  
Neubig R, 519  
Nies AS, 258

Nihira H, 290  
Nurmi A-K, 443

**O**

Ochs HR, 595, 648, 697  
Ohchi N, 462  
Okumura K, 290  
Omae T, 462  
Onoyama K, 462  
Overdiek HWP, 469  
Owen JA, 228

**P**

Paladine JA, 52  
Palmer M, 77  
Park GD, 350  
Patterson SE, 423  
Peck AW, 381  
Pedneault L, 686  
Perlman M, 680  
Persson B, 188  
Pettersson A, 188  
Phaneuf D, 686  
Philipson R, 381  
Piontek K, 150  
Pison C, 686  
Pitkäjärvi T, 443  
Poisson M, 686  
Presig R, 618  
Preston KL, 219, 544  
Procknal JA, 6  
Ptachcinski RJ, 296  
Puddu P, 101  
Pyykönen M-L, 443

**R**

Rakhit A, 251  
Raskin P, 625  
Ray WA, 402  
Regårdh CG, 205  
Regent MC, 6  
Reid JL, 560  
Reidenberg MM, 2  
Reilly CS, 579  
Reilly PA, 325  
Reinhardt LA, 273  
Renwick AG, 387  
Riddell JG, 554  
Roberts DG, 258  
Rolston K, 134  
Rönn O, 205  
Rose JE, 450  
Rosenkranz B, 652  
Rosenstock J, 625

Rosenthal JT, 296  
Rothbard RL, 84  
Roy SD, 128  
Rubin PC, 560  
Ruo TI, 318  
Ryder S, 625

**S**

San L, 336  
Saris S, 661  
Saucedo R, 365  
Schenck-Gustafsson K, 37  
Schmid B, 618  
Schneider BE, 16  
Schramm NT, 572  
Schreiner BF, 84  
Schwartz JB, 342  
Schwartz ML, 457  
Scully BE, 590  
Sepkovic DW, 164  
Seppälä E, 443  
Shader RI, 697  
Shanks RG, 554  
Shapiro S, 183  
Sharp T, 28  
Sheiner LB, 481  
Shenfield GM, 371  
Shepherd AMM, 475 (letter)  
Silas JH, 409  
Silke B, 266  
Sitar DS, 228  
Sjöqvist F, 394  
Sjöval J, 241  
Sloan RS, 212

Slomka M, 195  
Smallridge RC, 12  
Smith CV, 566  
Smith JL, 65  
Smith PC, 121  
Smith RB, 525  
Smith T, 625  
Smith V-E, 60  
Solé A, 336  
Sopko GS, 313  
Sörgel F, 306  
Soro S, 434  
Spector R, 350  
Spino M, 89  
Spruance SL, 56  
Steiner E, 394  
Stewart JT, 586  
Stitzer ML, 109  
Stoehr GP, 525  
St-Pierre MV, 89  
Straehl P, 140  
Streeter WC, 273  
Streicher J, 77  
Strom BL, 359  
Strong HA, 387  
Strong JM, 45

**T**

Tartiere J, 549  
Tashchian A, 572  
Taylor RJ, 296  
Taylor SH, 266  
Tesoro A, 89  
Thomas RW, 52

Thomassin C, 549  
Thomson ABR, 325  
Thrupp LD, 692  
Till A, 661  
Todd EL, 342, 566  
Tollemeto D, 101  
Tomooka S, 462  
Tosiello RL, 313  
Toto RD, 674  
Trilling Y, 450  
Tsuruda H, 462

**U**

Ugena B, 336  
Ulm E, 661

**V**

van den Ende A, 278  
van Herwaarden CLA, 428  
van Marion WF, 301  
van Ouwerkerk W, 301  
van Tol RGL, 278  
van Wayjen RGA, 278  
Vapaatalo H, 443  
Vega C, 686  
Venkataramanan R, 296  
Verburg-Ochs B, 595  
Verma P, 12  
Verma SP, 266  
Vesell ES, 603  
Vinson GA, 285  
Vlachakis ND, 503  
Vogelgesang B, 71

Vokonas PS, 509  
von Bahr C, 37

**W**

Wagner WE, 251  
Waldes L, 251  
Walker BR, 16  
Walle T, 509  
Walshe J, 150  
Ward JW, 409  
Warner NJ, 387  
Wearley L, 77  
Weinbrenner J, 648  
Wenestron G, 56  
Westerlund D, 241  
White WB, 60  
Wilkin JK, 273  
Wilkinson GR, 402  
Williams FL, 419  
Williams RL, 306  
Wood AJJ, 579  
Wood M, 579  
Wynder EL, 164

**Y**

Yaffe SJ, 183  
Yeo E, 134  
Ylitalo P, 443  
Yu PN, 84

**Z**

Zacny JP, 109  
Zanella MT, 613  
Zerbe GO, 258

## Subject index

### A

#### **Acebutolol**

Circulatory effects of intravenous and oral acebutolol in acute myocardial infarction (Silke et al), 266

#### **Acifran**

Controlled trial of acifran in type II hyperlipoproteinemia (Hunninghake et al), 313

#### **Acyl glucuronides**

Effect of probenecid on the formation and elimination of acyl glucuronides: Studies with zomepirac (Smith et al), 121

#### **Acrivastine**

Acrivastine (USAN List No. 266), 602

The acute effects of acrivastine (BW825C), a new antihistamine, compared with triprolidine on measures of central nervous system performance and subjective effects (Cohen et al), 381

#### **Adverse reaction(s)**

A study of adverse reaction algorithms in a drug surveillance program (Louik et al), 183

#### **Age**

Age, sex, and nitrazepam kinetics: Relation to antipyrine disposition (Greenblatt et al), 697

Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac (Sitar et al), 228

Gastrointestinal absorption as a function of age: Xylose absorption in healthy adults (Johnson et al), 331

Salicylate kinetics in old age (Netter et al), 6

#### **Alacepril**

Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states (Onoyama et al), 462

#### **Alcohol**

Effect of acute alcohol consumption on lithium kinetics (Anton et al), 52

#### **Aldosterone**

Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure (Zanella et al), 613

#### **Algorithm(s)**

A new dosing regimen in renal insufficiency: Application to cephalixin (Hori et al), 290

A study of adverse reaction algorithms in a drug surveillance program (Louik et al), 183

#### **Alpha-receptor(s)**

Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity (Alradi and Caruthers), 495

Pharmacologic reduction of sympathetic drive increases platelet alpha-2-receptor number (Egan et al), 519

#### **Alprazolam**

Effect of alprazolam on digoxin kinetics and creatinine clearance (Ochs et al), 595

#### **American Society for Clinical Pharmacology and Therapeutics**

A letter to the Members, 704

A message from the President, 235

Donors, 478

Status report from the Council on Clinical Pharmacology, July 1985, 599

#### **Amfilcon A**

Amfilcon A (USAN List No. 262), 117

#### **Aminoglycosides**

Effect of aminoglycosides on the disposition of thyroid hormones and thyroglobulin (du Souich et al), 686

#### **Amoxycillin**

Dose-dependent absorption of amoxycillin and bacampicillin (Sjövall et al), 241

#### **Analgesia**

Reassessment of verbal and visual analog ratings in analgesic studies (Littman et al), 16

#### **Analog scales**

Reassessment of verbal and visual analog ratings in analgesic studies (Littman et al), 16

#### **Angiotensin**

Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises (DiPette et al), 199

Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure (Zanella et al), 613

Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states (Onoyama et al), 462

July, pp 1-120; August, pp 121-240; September, 241-358; October, pp 359-480; November, pp 481-602; December, pp 603-724.

### Antagonist(s)

Effects of the calcium antagonist tiapamil on pulmonary gas exchange in patients with chronic obstructive pulmonary disease who receive salbutamol (Gugger et al), 96

Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine (Ochs et al), 648

### Antihistamine

The acute effects of acrivastine (BW825C), a new antihistamine, compared with triprolidine on measures of central nervous system performance and subjective effects (Cohen et al), 381

### Antihypertensive effect

Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol (Ylitalo et al), 443

### Antipyrine

Age, sex, and nitrazepam kinetics: Relation to antipyrine disposition (Greenblatt et al), 697

### Arthroscopy

Prilocaine in arthroscopy: Clinical pharmacokinetics and rational use (Debruyne et al), 549

### Asthma

Ventilatory effects of atenolol and bevantolol in asthma (Lammers et al), 428

### Astifilcon A

Astifilcon A (USAN List No. 265), 480

### Atenolol

Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses (Riddell and Shanks), 554

Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol (Ylitalo et al), 443

Ventilatory effects of atenolol and bevantolol in asthma (Lammers et al), 428

### Atropine

Atropine serum concentrations after multiple inhaled doses of atropine sulfate (Kradjan et al), 12

## B

### Bacampicillin

Dose-dependent absorption of amoxycillin and bacampicillin (Sjövall et al), 241

### Baclofen

The pharmacokinetics of baclofen derived from intestinal infusion (Kochak et al), 251

### Bactericide

The pharmacokinetics and bactericidal characteristics of oral cefixime (Brittain et al), 590

### Beta-adrenoceptor(s)

Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses (Riddell and Shanks), 554

### Beta-blocker(s)

Biologic determinants of propranolol disposition: Results from 1308 patients in the Beta-blocker Heart Attack Trial (Walle et al), 509

Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin (McGourty et al), 409

Ultra-short-acting beta-blockade: A comparison with conventional beta-blockade (Reilly et al), 579

### Betaxolol

Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses (Riddell and Shanks), 554

### Benzodiazepine

Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction (Kroboth et al), 525

### Bevantolol

Ventilatory effects of atenolol and bevantolol in asthma (Lammers et al), 428

### Blood flow

Prostaglandins and nicotinate-provoked increase in cutaneous blood flow (Wilkin et al), 273

### Blood loss

Fecal blood loss during isoxicam and piroxicam administration for 28 days (Hooper et al), 533

### Blood pressure

Effects of chronic nitrendipine on casual (office) and 24-hour ambulatory blood pressure (White et al), 60

### Books received

Book received, 358

### Breast milk

Sulbactam kinetics and excretion into breast milk in postpartum women (Foulds et al), 692

### Bupropion

Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose (Laizure et al), 586

### Butylated hydroxytoluene

Treatment of recurrent herpes simplex labialis with topical butylated hydroxytoluene (Freeman et al), 56

## C

### Cancer

Epidural and intrathecal opiates: Cerebrospinal fluid and plasma profiles in patients with chronic cancer pain (Max et al), 631

### Cannabinoid

Excretion patterns of cannabinoid metabolites after last use in a group of chronic users (Ellis et al), 572

### Captopril

Effect of naloxone on the actions of captopril (Ajayi et al), 560



**Caucasian**

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations (Nakamura et al), 402

**Cefixime**

The pharmacokinetics and bactericidal characteristics of oral cefixime (Brittain et al), 590

**Cefotaxime**

Cefotaxime and desacetyl cefotaxime kinetics in renal impairment (Matzke et al), 31

Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis (Albin et al), 285

**Central nervous system**

The acute effects of acrivastine (BW825C), a new antihistamine, compared with triprolidine on measures of central nervous system performance and subjective effects (Cohen et al), 381

**Cephalexin**

A new dosing regimen in renal insufficiency: Application to cephalexin (Hori et al), 209

**Cerebrospinal fluid**

Epidural and intrathecal opiates: Cerebrospinal fluid and plasma profiles in patients with chronic cancer pain (Max et al), 631

**Cetirizine hydrochloride**

Cetirizine hydrochloride (USAN List No. 262), 117

**Charcoal**

Lack of effect of oral activated charcoal on imipramine clearance (Goldberg et al), 350

**Chronic obstructive pulmonary disease**

Effects of the calcium antagonist tiapamil on pulmonary gas exchange in patients with chronic obstructive pulmonary disease who receive salbutamol (Gugger et al), 96

**Cigarette(s)**

Cigarette smoking as a risk for cardiovascular disease. Part VI. Compensation with nicotine availability as a single variable (Haley et al), 164

Transdermal nicotine reduces cigarette craving and nicotine preference (Rose et al), 450

**Cimetidine**

Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam (Klotz et al), 652

Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine (Ochs et al), 648

Lack of interaction between verapamil and cimetidine (Abernethy et al), 342

Lack of pharmacokinetic interaction between cimetidine and pirenzepine (Jamali et al), 325

**Ciramadol**

Hemodynamic and respiratory effects of dezocine, ciramadol, and morphine (Rothbard et al), 84

Oral ciramadol in the treatment of postoperative pain (Lasagna and Calimlim), 177

**Cirrhosis**

Pefloxacin kinetics in cirrhosis (Danan et al), 439

**Clavulanic acid**

Clinical pharmacology of ticarcillin and clavulanic acid (Bodey et al), 134

**Clinical pharmacology**

Clinical pharmacology: A personal perspective (Vesell), 603

Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation (Klecker et al), 45

Clinical pharmacology of ticarcillin and clavulanic acid (Bodey et al), 134

The discipline of clinical pharmacology (Reidenberg), 2

**Clonidine**

Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin (Camí et al), 336

Pharmacokinetics of transdermally delivered clonidine (MacGregor et al), 278

Self-administration of clonidine, oxazepam, and hydro-morphine by patients undergoing methadone detoxification (Preston et al), 219

**Cocaine**

Kinetics of cocaine distribution, elimination, and chronotropic effects (Chow et al), 318

**Colon**

Sulindac metabolism: The importance of an intact colon (Strong et al), 387

**Computer(s)**

Computerized assessment of human neurotoxicity: Sensitivity to nitrous oxide exposure (Greenberg et al), 656

The computerized on-line Medicaid pharmaceutical analysis and surveillance system: A new resource for post-marketing drug surveillance (Strom et al), 359

**Continuous ambulatory peritoneal dialysis**

Moxalactam epimer disposition in patients undergoing continuous ambulatory peritoneal dialysis (Morse et al), 150

Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis (Albin et al), 285

**Contraceptive(s)**

Interactions between ethanol and oral contraceptive steroids (Hobbes et al), 371

**Creatinine**

Effect of alprazolam on digoxin kinetics and creatinine clearance (Ochs et al), 595

**Cyclosporine**

Cyclosporine kinetics in renal transplantation (Ptachcinski et al), 296



## D

### Debrisoquin

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin (Steiner et al), 394

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations (Nakamura et al), 402

Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin (Roy et al), 128

Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin (McGourty et al), 409

Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation (Schmid et al), 618

### Demethylation

Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation (Schmid et al), 618

### Desacetyl cefotaxime

Cefotaxime and desacetyl cefotaxime kinetics in renal impairment (Matzke et al), 31

### Detoxification

Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin (Camf et al), 336

Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification (Preston et al), 219

### Dextromethorphan

Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation (Schmid et al), 618

### Dezocine

Assessment of dezocine for morphine-like subjective effects and miosis (Jasinski and Preston), 544

Hemodynamic and respiratory effects of dezocine, ciramadol, and morphine (Rothbard et al), 84

### Diabetes

Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes (Raskin et al), 625

### Digitoxin

Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin (Kuhlmann), 667

### Digoxin

Effect of alprazolam on digoxin kinetics and creatinine clearance (Ochs et al), 595

### Diltiazem

Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin (Kuhlmann), 667

### Disease

Cigarette smoking as a risk for cardiovascular disease. Part VI. Compensation with nicotine availability as a single variable (Haley et al), 164

Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac (Sitar et al), 228

Effects of the calcium antagonist tiapamil on pulmonary gas exchange in patients with chronic obstructive pulmonary disease who receive salbutamol (Gugger et al), 96

### Disopyramide

Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects (Chiang et al), 37

### Dosing regimen (see algorithm)

### Drug marketing

Premarketing observational studies of population pharmacokinetics of new drugs (Sheiner and Benet), 481

The computerized on-line Medicaid pharmaceutical analysis and surveillance system: A new resource for post-marketing drug surveillance (Strom et al), 359

## E

### Enalapril

The effect of renal function on enalapril kinetics (Lowenthal et al), 661

### Enalaprilat

Enalaprilat, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises (DiPette et al), 199

### Enprofylline

Enprofylline (USAN List No. 267), 705

### Environment

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin (Steiner et al), 394

### Enzyme

Enalaprilat, an intravenous angiotensin converting enzyme inhibitor, in hypertensive crises (DiPette et al), 199

Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure (Zanella et al), 613

Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states (Onoyama et al), 462

### Epimer

Moxalactam epimer disposition in patients undergoing continuous ambulatory peritoneal dialysis (Morse et al), 150

### Ethanol

The effects of several weeks of ethanol consumption on ethanol kinetics in normal men and women (Holtzman et al), 157

Interactions between ethanol and oral contraceptive steroids (Hobbes et al), 371

### Ethnic differences

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations (Nakamura et al), 402

**Etodolac**

Effect of etodolac in patients with moderate renal impairment compared with normal subjects (Brater et al), 674

**Errata**

Alpha-methyldopa disposition in mothers with hypertension and in their breast-fed infants (White et al), 317

Tolrestat kinetics (Hicks et al), 317

**F****Feces**

Fecal blood loss during isoxicam and piroxicam administration for 28 days (Hooper et al), 533

**Felodipine**

Felodipine (USAN List No. 267), 705

Felodipine kinetics in healthy men (Edgar et al), 205

**Flebotol sulfate**

Flebotol sulfate (USAN List No. 262), 118

**Food**

Concomitant food intake does enhance the bioavailability and effect of hydralazine (Melander et al), 475 (letter)

Food induced changes in theophylline absorption from controlled-release formulations (Karim et al)

I. Substantial increased and decreased absorption with Uniphyll tablets and Theo-Dur Sprinkle, 77

II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption, 642

**Fosarilate**

Fosarilate (USAN List No. 264), 357

**Furegrelate sodium**

Furegrelate sodium (USAN List No. 264), 356

**G****Gastric (see stomach)****Gastrointestinal (see stomach, intestine)****Genetics**

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin (Steiner et al), 394

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations (Nakamura et al), 402

**Gentamicin**

A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn (Koren et al), 680

**Glomerular filtration rate**

A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn (Koren et al), 680

**H****Hand vein**

Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity (Alradi and Caruthers), 495

**Heart**

Biologic determinants of propranolol disposition: Results from 1308 patients in the Beta-blocker Heart Attack Trial (Walle et al), 509

Cigarette smoking as a risk for cardiovascular disease. Part VI. Compensation with nicotine availability as a single variable (Haley et al), 164

Determinants of systemic availability of oral hydralazine in heart failure (Crawford et al), 538

Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism (Echizen et al), 71

**Hemostasis**

Pentosane polysulfate: The effect on hemostasis of a continuous 3-day infusion (de Prost et al), 171

**Heroin**

Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin (Camí et al), 336

**Herpes simplex labialis**

Treatment of recurrent herpes simplex labialis with topical butylated hydroxytoluene (Freeman et al), 56

**Histamine**

Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine (Ochs et al), 648

Morphine-induced skin wheals: A possible model for the study of histamine release (Saucedo and Erill), 365

**Histrelin**

Histrelin (USAN List No. 267), 706

**Hormones**

Effect of aminoglycosides on the disposition of thyroid hormones and thyroglobulin (du Souich et al), 686

**Hydralazine**

Concomitant food intake does enhance the bioavailability and effect of hydralazine (Melander et al), 475 (letter)

Determinants of systemic availability of oral hydralazine in heart failure (Crawford et al), 538

**Hydrazine**

Oxidation of hydrazine metabolites formed from isoniazid (Lauterburg et al), 566

**Hydrochlorothiazide**

Labetalol and hydrochlorothiazide in hypertension (Labetalol/Hydrochlorothiazide Multicenter Study Group), 24

**Hydromorphone**

Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification (Preston et al), 219

## Hydroxylation

- A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin (Steiner et al), 394
- Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations (Nakamura et al), 402
- Mephenytoin hydroxylation polymorphism: Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo (Meier et al), 488
- Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation (Schmid et al), 618
- Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation (Küpfer and Branch), 414

## Hyperkalemia

- Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure (Zanella et al), 613

## Hyperlipoproteinemia

- Controlled trial of acifran in type II hyperlipoproteinemia (Hunninghake et al), 313

## Hypertension

- Antihypertensive and cardiovascular effects of nitrendipine: A controlled study vs. placebo (Ferrara et al), 434
- Enalaprilate, an intravenous angiotensin-converting enzyme inhibitor, in hypertensive crises (DiPette et al), 199
- Labetalol and hydrochlorothiazide in hypertension (Labetalol/Hydrochlorothiazide Multicenter Study Group), 24
- Losulazine, a new antihypertensive (Gore et al), 195
- Treatment of arterial hypertension with ketanserin in mono- and combination therapy (Pettersson et al), 188

## I

### Ibuprofen

- Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine (Ochs et al), 648

### Icotidine

- Icotidine (USAN List No. 265), 480

### Iloprost

- Myocardial ischemia induced by prostacyclin and iloprost (Bugiardi et al), 101

### Imipramine

- Lack of effect of oral activated charcoal on imipramine clearance (Goldberg et al), 350

### Indolapril hydrochloride

- Indolapril hydrochloride (USAN List No. 265), 480

### Indomethacin

- Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol (Ylitalo et al), 443

## Infarction

- Circulatory effects of intravenous and oral acebutolol in acute myocardial infarction (Silke et al), 266

## Inhalation (see specific drug)

## Inhibition

- Enalaprilat, an intravenous angiotensin converting enzyme inhibitor, in hypertensive crises (DiPette et al), 199
- Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure (Zanella et al), 613
- Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states (Onoyama et al), 462

## Interaction(s)

- Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol (Ylitalo et al), 443
- Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine (Ochs et al), 648
- Interactions between ethanol and oral contraceptive steroids (Hobbes et al), 371
- Lack of interaction between verapamil and cimetidine (Abernethy et al), 342
- Lack of pharmacokinetic interaction between cimetidine and pirenzepine (Jamali et al), 325

## Intestine

- Gastrointestinal absorption as a function of age: Xylose absorption in healthy adults (Johnson et al), 331
- The pharmacokinetics of baclofen derived from intestinal infusion (Kochak et al), 251

## 5-Iodo-2'-deoxyuridine

- Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation (Klecker et al), 45

## 5-Iodouracil

- Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation (Klecker et al), 45

## Ischemia

- Myocardial ischemia induced by prostacyclin and iloprost (Bugiardi et al), 101

## Isoniazid

- Oxidation of hydrazine metabolites formed from isoniazid (Lauterburg et al), 566

## Isoproterenol

- Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses (Riddell and Shanks), 554

## Isosorbide dinitrate

- Isosorbide dinitrate bioavailability, kinetics, and metabolism (Straehl and Galeazzi), 140

## Isoxicam

- Fecal blood loss during isoxicam and piroxicam administration for 28 days (Hooper et al), 533

**J****Japanese**

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations (Nakamura et al), 402

**K****Ketanserin**

Treatment of arterial hypertension with ketanserin in mono- and combination therapy (Pettersson et al), 188

**Kidney**

A new dosing regimen in renal insufficiency: Application to cephalexin (Hori et al), 209

A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn (Koren et al), 680

Cefotaxime and desacetyl cefotaxime kinetics in renal impairment (Matzke et al), 31

Cyclosporine kinetics in renal transplantation (Ptachcinski et al), 296

Effect of etodolac in patients with moderate renal impairment compared with normal subjects (Brater et al), 674

Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin (Kuhlmann), 667

Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure (Zanella et al), 613

Nitrendipine kinetics in normal and impaired renal function (Aronoff and Sloan), 212

Sulindac is not renal sparing in man (Roberts et al), 258  
The effect of renal function on enalapril kinetics (Lowenthal et al), 661

**L****Labetalol**

Labetalol and hydrochlorothiazide in hypertension (Labetalol/Hydrochlorothiazide Multicenter Study Group), 24

Pharmacodynamics of intravenous labetalol and follow-up therapy with oral labetalol (Vlachakis et al), 503

**Lamotrigine**

Lamotrigine (USAN List No. 264), 356

**Linear variable differential transformer**

Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity (Alradi and Caruthers), 495

**Lithium**

Effect of acute alcohol consumption on lithium kinetics (Anton et al), 52

**Liver**

Mephenytoin hydroxylation polymorphism: Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo (Meier et al), 488

**Losulazine**

Losulazine, a new antihypertensive (Gore et al), 195

**Lung**

Effects of the calcium antagonist tiapamil on pulmonary gas exchange in patients with chronic obstructive pulmonary disease who receive salbutamol (Gugger et al), 96

**Lupitidine hydrochloride**

Lupitidine hydrochloride (USAN List No. 263), 237

**M****Maduramicin**

Maduramicin (USAN List No. 263), 238

**Medicaid**

The computerized on-line Medicaid pharmaceutical analysis and surveillance system: A new resource for post-marketing drug surveillance (Strom et al), 359

**Mephenytoin**

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations (Nakamura et al), 402

Mephenytoin hydroxylation polymorphism: Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo (Meier et al), 488

Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation (Küpfer and Branch), 414

**Mephobarbital**

Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation (Küpfer and Branch), 414

**Metabolism**

Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism (Echizen et al), 71

Excretion patterns of cannabinoid metabolites after last use in a group of chronic users (Ellis et al), 572

Isosorbide dinitrate bioavailability, kinetics, and metabolism (Straehl and Galeazzi), 140

Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects (Chiang et al), 37

Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin (Roy et al), 128

Oxidation of hydrazine metabolites formed from isoniazid (Lauterburg et al), 566

Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose (Laizure et al), 586

Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation (Schmid et al), 618

Sulindac metabolism: The importance of an intact colon (Strong et al), 387

Temporal variation in the disposition of theophylline and its metabolites (St-Pierre et al), 89

**Metabolite(s)** (see metabolism, specific drug)

**Methadone**

Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin (Camf et al), 336

Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification (Preston et al), 219

**Methoxyphenamine**

Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin (Roy et al), 128

**Midazolam**

Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam (Klotz et al), 652

**Miosis**

Assessment of dezocine for morphine-like subjective effects and miosis (Jasinski and Preston), 544

**Morphine**

Assessment of dezocine for morphine-like subjective effects and miosis (Jasinski and Preston), 544

Hemodynamic and respiratory effects of dezocine, ciramadol, and morphine (Rothbard et al), 84

Morphine-induced skin wheals: A possible model for the study of histamine release (Saucedo and Erill), 365

**Motion sickness**

Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas (van Marion et al), 301

**Moxalactam**

Moxalactam epimer disposition in patients undergoing continuous ambulatory peritoneal dialysis (Morse et al), 150

**Mucosa**

Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa (Graham et al), 65

**N**

**Naloxone**

Effect of naloxone on the actions of captopril (Ajayi et al), 560

**Naltrexone**

Effects of long-term therapy with naltrexone on body weight in obesity (Atkinson et al), 419

**Napamezole hydrochloride**

Napamezole hydrochloride (USAN List No. 264), 357

**Nefocon A**

Nefocon A (USAN List No. 266), 602

**Neurotoxicity**

Computerized assessment of human neurotoxicity: Sensitivity to nitrous oxide exposure (Greenberg et al), 656

**Newborn**

A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn (Koren et al), 680

**Nicotinate**

Prostaglandins and nicotinate-provoked increase in cutaneous blood flow (Wilkin et al), 273

**Nicotine**

Cigarette smoking as a risk for cardiovascular disease. Part VI. Compensation with nicotine availability as a single variable (Haley et al), 164

Transdermal nicotine reduces cigarette craving and nicotine preference (Rose et al), 450

**Nicotine polacrilex**

Nicotine polacrilex (USAN List No. 266), 601

**Nifedipine**

Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin (Kuhlmann), 667

**Nitrazepam**

Age, sex, and nitrazepam kinetics: Relation to antipyrine disposition (Greenblatt et al), 697

**Nitrendipine**

Antihypertensive and cardiovascular effects of nitrendipine: A controlled study vs. placebo (Ferrara et al), 434

Effects of chronic nitrendipine on casual (office) and 24-hour ambulatory blood pressure (White et al), 60

Nitrendipine kinetics in normal and impaired renal function (Aronoff and Sloan), 212

**Nitrous oxide**

Computerized assessment of human neurotoxicity: Sensitivity to nitrous oxide exposure (Greenberg et al), 656

**Nonsteroidal anti-inflammatory drugs**

Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa (Graham et al), 65

**Notes**

A note from the Co-Editor, 1

Notes of the ASCPT (see American Society for Clinical Pharmacology)

**O**

**Obesity**

Effects of long-term therapy with naltrexone on body weight in obesity (Atkinson et al), 419

**Opiate(s)**

Epidural and intrathecal opiates: Cerebrospinal fluid and plasma profiles in patients with chronic cancer pain (Max et al), 631

**Oral contraceptive(s)**

Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction (Kroboth et al), 525

**Oxazepam**

Self-administration of clonidine, oxazepam, and hydromorphone by patients undergoing methadone detoxification (Preston et al), 219



**Oxidation**

Oxidation of hydrazine metabolites formed from isoniazid (Lauterburg et al), 566

**Oximonam**

Oximonam (USAN List No. 267), 706

Oximonam sodium (USAN List No. 267), 706

**P****Pain**

Epidural and intrathecal opiates: Cerebrospinal fluid and plasma profiles in patients with chronic cancer pain (Max et al), 631

Oral ciramadol in the treatment of postoperative pain (Lassagna and Calimlim), 177

**Pefloxacin**

Pefloxacin kinetics in cirrhosis (Danan et al), 439

**Pelrinone hydrochloride**

Pelrinone hydrochloride (USAN List No. 262), 118

**Pentobarbital**

Pharmacokinetics of high-dose pentobarbital in severe head trauma (Bayliff et al), 457

**Pentopril**

Pentopril (USAN List No. 262), 118

**Pentosane polysulfate**

Pentosane polysulfate: The effect on hemostasis of a continuous 3-day infusion (de Prost et al), 171

**Pirenzepine**

Lack of pharmacokinetic interaction between cimetidine and pirenzepine (Jamali et al), 325

**Piroxicam**

Fecal blood loss during isoxicam and piroxicam administration for 28 days (Hooper et al), 533

**Platelet(s)**

Pharmacologic reduction of sympathetic drive increases platelet alpha-2-receptor number (Egan et al), 519

**Polybutester**

Polybutester (USAN List No. 263), 238

**Postpartum women**

Sulbactam kinetics and excretion into breast milk in postpartum women (Foulds et al), 692

**Potassium chloride**

Endoscopic evaluation of slow-release potassium chloride preparations (Kendall et al), 28

**Prilocaine**

Prilocaine in arthroscopy: Clinical pharmacokinetics and rational use (Debruyne et al), 549

**Probenecid**

Effect of probenecid on the formation and elimination of acyl glucuronides: Studies with zomepirac (Smith et al), 121

**Propranolol**

Biologic determinants of propranolol disposition: Results from 1308 patients in the Beta-blocker Heart Attack Trial (Walle et al), 509

Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses (Riddell and Shanks), 554

**Prostacyclin**

Myocardial ischemia induced by prostacyclin and iloprost (Bugiardini et al), 101

**Prostaglandin(s)**

Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol (Ylitalo et al), 443

Prostaglandins and nicotine-provoked increase in cutaneous blood flow (Wilkin et al), 273

**Pulmonary** (see lung)**Q****Quadazocine mesylate**

Quadazocine mesylate (USAN List No. 264), 356

**Quinapril hydrochloride**

Quinapril hydrochloride (USAN List No. 263), 237

**R****Ranitidine**

Effect of single doses of cimetidine and ranitidine on the steady-state plasma levels of midazolam (Klotz et al), 652

Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine (Ochs et al), 648

**Recainam**

Recainam hydrochloride (USAN List No. 264), 357

Recainam tosylate (USAN List No. 265), 479

**Reclazepam**

Reclazepam (USAN List No. 266), 602

**Red blood cells**

Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes (Raskin et al), 625

**Remoxipride**

Remoxipride (USAN List No. 262), 117

**Renal** (see kidney)**Reviewers**

List of reviewers to volume 37, 477

**Rifapentine**

Rifapentine (USAN List No. 263), 237

**S****Salbutamol**

Effects of the calcium antagonist tiapamil on pulmonary gas exchange in patients with chronic obstructive pulmonary disease who receive salbutamol (Gugger et al), 96

**Salicylate**

Salicylate kinetics in old age (Netter et al), 6

**Salmeterol**

Salmeterol (USAN List No. 267), 705

### Scopolamine

Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas (van Marion et al), 301

### Sex

Age, sex, and nitrazepam kinetics: Relation to antipyrine disposition (Greenblatt et al), 697

### Smoking

Cigarette smoking as a risk for cardiovascular disease. Part VI. Compensation with nicotine availability as a single variable (Halcy et al), 164

Effects of smoke deprivation interval on puff topography (Zacny and Stitzer), 109

### Spironolactone

New insights into the pharmacokinetics of spironolactone (Overdiek et al), 469

### Steroids

Interactions between ethanol and oral contraceptive steroids (Hobbes et al), 371

### Stomach

Gastrointestinal absorption as a function of age: Xylose absorption in healthy adults (Johnson et al), 331

Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa (Graham et al), 65

### Sulbactam

Sulbactam kinetics and excretion into breast milk in postpartum women (Foulds et al), 692

### Sulindac

Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac (Sitar et al), 228

Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa (Graham et al), 65

Sulindac is not renal sparing in man (Roberts et al), 258

Sulindac metabolism: The importance of an intact colon (Strong et al), 387

### Surfilcon A

Surfilcon A (USAN List No. 265), 479

### Sympathetic system

Pharmacologic reduction of sympathetic drive increases platelet alpha-2-receptor number (Egan et al), 519

## T

### Temocillin

Temocillin (USAN List No. 266), 601

### Temporal variation

Temporal variation in the disposition of theophylline and its metabolites (St-Pierre et al), 89

### Terazosin

Terazosin kinetics after oral and intravenous doses (Patterson), 423

### Theophylline

Food-induced changes in theophylline absorption from controlled-release formulations (Karim et al)

I. Substantial increased and decreased absorption with Uniphyll tablets and Theo-Dur Sprinkle, 77

II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption, 642

Temporal variation in the disposition of theophylline and its metabolites (St-Pierre et al), 89

### Thyroid

Effect of aminoglycosides on the disposition of thyroid hormones and thyroglobulin (du Souich et al), 686

### Thyroglobulin

Effect of aminoglycosides on the disposition of thyroid hormones and thyroglobulin (du Souich et al), 686

### Tiapamil

Effects of the calcium antagonist tiapamil on pulmonary gas exchange in patients with chronic obstructive pulmonary disease who receive salbutamol (Gugger et al), 96

### Ticarcillin

Clinical pharmacology of timentin (ticarcillin and clavulanic acid) (Bodey et al), 134

### Timentin

Clinical pharmacology of timentin (ticarcillin and clavulanic acid) (Bodey et al), 134

### Timolol

Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin (McGourty et al), 409

### Tolrestat

Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes (Raskin et al), 625

### Transplantation

Cyclosporine kinetics in renal transplantation (Ptachcinski et al), 296

### Transdermal (see specific drug)

### Trauma

Pharmacokinetics of high-dose pentobarbital in severe head trauma (Bayliff et al), 457

### Triamterene

Oral triamterene disposition (Sörgel et al), 306

### Tripolidine

The acute effects of acrivastine (BW825C), a new antihistamine, compared with tripolidine on measures of central nervous system performance and subjective effects (Cohen et al), 381

### Trospectomycin sulfate

Trospectomycin sulfate (USAN List No. 262), 118

### Tubulazole hydrochloride

Tubulazole hydrochloride (USAN List No. 266), 601

## V

### Verapamil

Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism (Echizen et al), 71



Effects of verapamil, diltiazem, and nifedipine on plasma levels and renal excretion of digitoxin (Kuhlmann), 667  
Lack of interaction between verapamil and cimetidine (Abernethy et al), 342

**Viprostol**

Viprostol (USAN List No. 264), 357

**W**

**Wheals**

Morphine-induced skin wheals: A possible model for the study of histamine release (Saucedo and Erill), 365

**X**

**Xylose**

Gastrointestinal absorption as a function of age: Xylose absorption in healthy adults (Johnson et al), 331

**Z**

**Zomepirac**

Effect of probenecid on the formation and elimination of acyl glucuronides: Studies with zomepirac (Smith et al), 121

